(Q84019032)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21537347%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

title

Outcomes of extremely low risk prostate cancer following radical prostatectomy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21537347%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

E W Lee

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21537347%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

J Laze

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21537347%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

H Lepor

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21537347%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

3 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21537347%20AND%20SRC:MED&resulttype=core&format=json

Prostate Cancer and Prostatic Diseases

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21537347%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21537347%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21537347%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

266-269

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21537347%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/pcan.2011.21

30 January 2020

exact match

0 references

cites work

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Percent tumor involvement and risk of biochemical progression after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Radical retropubic prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Natural history of progression after PSA elevation following radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.21

31 March 2020

Identifiers

DOI

10.1038/PCAN.2011.21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21537347%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference